RSV - Respiratory Syncytial Virus

What is RSV?

  • RSV is a respiratory virus, occurring during cold seasons around the world.
  • Globally RSV is responsible for more than 30 million infections every year.
  • In infants under 2, RSV is the most common cause of bronchiolitis and pneumonia. The mortality rate for hospitalised infants is between 2-3% in most developed countries, including the US.
  • High-risk populations include: premature infants, children with congenital heart or lung disease, those with weakened immune systems, people with immunodeficiencies, the elderly, and adults with CHF or COPD.
  • There are currently no licensed antivirals for widespread use in treating RSV infection.

    Facts about RSV

Product Pipeline

ReViral is focused on the discovery and development of the next generation of antivirals to treat RSV infection.

Sisunatovir:

  • A potent, novel, oral small molecule RSV (A&B) fusion (F) inhibitor.
  • Phase 1 clinical trial showed good safety profile and exposure that exceeds levels predicted for antiviral activity.
  • Highly potent activity measured by viral load and symptoms in Phase 2a adult challenge model.
  • Entering an international multicentre Phase 2 paediatric trial.


RSV N Protein Inhibitors:

  • Small molecule RSV (A&B) N protein inhibitors are in preclinical studies.

Reviral Pipeline

Publications

State of the Art in Respiratory Syncytial Virus Drug Discovery and Development. Journal of Medicinal Chemistry Perspective. (2018). G. Stuart Cockerill, James A. D. Good, and Neil Mathews. 

Antiviral drugs for acute infections. Comprehensive Medicinal Chemistry III. (2017), Vol 5, Pages 665-681, Powell, KL., Thomas, E., and Cockerill, GS.

The prophylaxis and treatment with antiviral agents of respiratory syncytial virus infections. Antivir Chem Chemother. (2012) 17;22(4):139-50. Najarro, P., Angell, R., and Powell KL.

Inhibitors of Respiratory Syncytial Virus. Annual Reports in Medicinal Chemistry. (2008), Vol. 43, Chapter 14. Pages. 229-245. Carter, M. and Cockerill, GS.

RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrobial Agents and Chemotherapy. (2007), 51(9), 3346-3353. Chapman, Joanna; Abbott, Elizabeth; Alber, Dagmar G.; Baxter, Robert C.; Bithell, Sian K.; Henderson, Elisa A.; Carter, Malcolm C.; Chambers, Phil; Chubb, Ann; Cockerill, G. Stuart; Collins, Peter L.; Dowdell, Verity C. L.; Keegan, Sally J.; Kelsey, Richard D.; Lockyer, Michael J.; Luongo, Cindy; Najarro, Pilar; Pickles, Raymond J.; Simmonds, Mark; Taylor, Debbie; Tyms, Stan; Wilson, Lara J.; Powell, Kenneth L

1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. Journal of Medicinal Chemistry. (2006), Vol 49, Pages 2311 – 2319. Malcolm C. Carter, Dagmar G. Alber, Robert C. Baxter, Sian K. Bithell, Jo Budworth, Ann Chubb, G. Stuart Cockerill, Verity C. L. Dowdell, Elisa A. Henderson, Sally J. Keegan, Richard D. Kelsey, Michael J. Lockyer, Jeremy N. Stables, Lara J. Wilson, and Kenneth L. Powell.